血管肉瘤治疗后的总生存率较低: 64 名患者的单中心回顾性观察队列研究
Sonja Kjartansdóttir1,2, Erik Malchau3,4, Christina Berger3,4
1Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. sonja.kristin.kjartansdottir@gu.se.
BMC cancer
|August 27, 2025
概括
这项关于血管肉瘤 (AS) 的研究发现主要 (pAS) 和次要 (sAS) 形式的局部复发率高 (60%). 与sAS (43. 5%) 相比,pAS的五年生存率明显较低.
科学领域:
- 癌症学
- 外科病理学
- 医疗恶性疾病
背景情况:
- 血管瘤 (AS) 是一种罕见的,高度恶性瘤,具有初级 (pAS) 和二级 (sAS) 形式.
- 由于辐射,化学暴露或斯图尔特-特雷夫综合征,
研究的目的:
- 描述血管瘤患者的临床表现,管理,治疗和结果.
- 分析AS患者的局部复发,转移和整体存活率.
主要方法:
- 在2000年至2020年期间对AS治疗的患者进行了回顾性单中心研究.
- 通过SNOMED代码M91203识别的患者数据,并从医疗记录中分析.
主要成果:
- 发现了64名AS患者 (37名pAS,27名sAS);平均年龄为67岁.
- 高局部复发率:pAS为65. 4%,sAS为63%.
- 五年整体存活率:pAS为10. 2%,sAS为43. 5%,研究结束时患者的存活率为23%.
结论:
- 这种疾病存在于不同位置,影响男性和女性.
- 乳腺癌主要发生在先前患有乳腺癌的妇女中,通常发生在胸部区域.
- 60%的局部复发率和生存差异凸显了AS的攻击性.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448


